Literature DB >> 8144855

Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance.

T Hoffmann1, C Penel, C Ronin.   

Abstract

To analyze the role of individual glycosylation pattern on PRL biopotency, monomeric prolactin (PRL), secreted by human prolactinoma cells in culture, was isolated by gel filtration and separated by affinity chromatography on Concanavalin A-Sepharose or Lentil-Agarose. These lectins allowed the isolation of PRL glycoforms containing either biantennary, mannose-rich or fucosylated complex carbohydrate structures, respectively. Endoglycosidase treatment and carbohydrate content of PRL was found to be consistent with N-linked oligosaccharides of mannose-rich structure and complex units terminated in sialic acid. Mannose-rich PRL and PRL with biantennary oligosaccharides promoted cell growth of rat lymphoma cells to a diminished extent compared to non-glycosylated PRL (NG-PRL), indicating that the two major types of carbohydrate structure are able to decrease the intrinsic bioactivity of PRL. Metabolic clearance of the various forms of PRL in rats was also found to be highly dependent upon hormone glycosylation. The various glycosylated forms (G-PRLs) proved to be totally eliminated from the circulation within 60 min, faster than NG-PRL 10% of which was still present at that time. Mannose-rich or biantennary G-PRLs were differently cleared in a biphasial fashion with a similar rapid phase of about 2 min followed by distinct slow phases of 12 and 27 min, respectively. The presence of fucose did not alter this distribution. In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. The distribution of PRL to target and elimination organs was also found to be different according to the carbohydrate structure present in the hormone. NG-PRL and mannose-rich G-PRL showed higher incorporation in liver than biantennary G-PRL which was preferentially eliminated by the kidney. Altogether, the current data show that addition of oligosaccharides to PRL as well as carbohydrate structure contribute to modulate both the duration of the hormone in the blood and its distribution to different organs. It is proposed that glycosylation may selectively down-regulate PRL action at individual target tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8144855     DOI: 10.1007/BF03348932

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

1.  Isolation and biochemical properties of four forms of glycosylated porcine prolactin.

Authors:  Y N Sinha; L V DePaolo; L S Haro; R N Singh; B P Jacobsen; K E Scott; U J Lewis
Journal:  Mol Cell Endocrinol       Date:  1991-09       Impact factor: 4.102

Review 2.  Role of carbohydrates in glycoprotein hormone signal transduction.

Authors:  M R Sairam
Journal:  FASEB J       Date:  1989-06       Impact factor: 5.191

3.  Glycosylated human prolactin.

Authors:  U J Lewis; R N Singh; Y N Sinha; W P Vanderlaan
Journal:  Endocrinology       Date:  1985-01       Impact factor: 4.736

4.  JANA: a new iterative polyexponential curve stripping program.

Authors:  A Dunne
Journal:  Comput Methods Programs Biomed       Date:  1985-08       Impact factor: 5.428

5.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

6.  Human growth hormone and extracellular domain of its receptor: crystal structure of the complex.

Authors:  A M de Vos; M Ultsch; A A Kossiakoff
Journal:  Science       Date:  1992-01-17       Impact factor: 47.728

7.  Further characterization of rat 26,000 prolactin as a glycoprotein with essentially o-linked carbohydrate chains.

Authors:  F Bollengier; R Hooghe; B Velkeniers; A Mahler; L Vanhaelst; E Hooghe-Peters
Journal:  J Neuroendocrinol       Date:  1991-08-01       Impact factor: 3.627

8.  Polymorphism of prolactin secreted by human prolactinoma cells: immunological, receptor binding, and biological properties of the glycosylated and nonglycosylated forms.

Authors:  I Pellegrini; G Gunz; C Ronin; E Fenouillet; J P Peyrat; P Delori; P Jaquet
Journal:  Endocrinology       Date:  1988-06       Impact factor: 4.736

9.  Molecular basis of recognition by the glycoprotein hormone-specific N-acetylgalactosamine-transferase.

Authors:  P L Smith; J U Baenziger
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

10.  The asparagine-linked oligosaccharides at individual glycosylation sites in human thyrotrophin.

Authors:  J Hiyama; G Weisshaar; A G Renwick
Journal:  Glycobiology       Date:  1992-10       Impact factor: 4.313

View more
  12 in total

1.  Glycosylated equine prolactin and its carbohydrate moiety.

Authors:  V Y Butnev; R R Gotschall; V L Baker; W T Moore; P W Gout; G R Bousfield
Journal:  J Protein Chem       Date:  1996-07

Review 2.  N-glycosylation/deglycosylation as a mechanism for the post-translational modification/remodification of proteins.

Authors:  T Suzuki; K Kitajima; S Inoue; Y Inoue
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

Review 3.  Prolactin as a mitogen in mammary cells.

Authors:  R Das; B K Vonderhaar
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

4.  Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans.

Authors:  Timothy M Block; Mary Ann Comunale; Melissa Lowman; Laura F Steel; Patrick R Romano; Claus Fimmel; Bud C Tennant; W Thomas London; Alison A Evans; Baruch S Blumberg; Raymond A Dwek; Tajinder S Mattu; Anand S Mehta
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-10       Impact factor: 11.205

5.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

6.  Bioactive prolactin levels and risk of breast cancer: a nested case-control study.

Authors:  Shelley S Tworoger; Megan S Rice; Bernard A Rosner; Yvonne B Feeney; Charles V Clevenger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-14       Impact factor: 4.254

7.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

8.  A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development.

Authors:  Shelley S Tworoger; A Heather Eliassen; Xuehong Zhang; Jing Qian; Patrick M Sluss; Bernard A Rosner; Susan E Hankinson
Journal:  Cancer Res       Date:  2013-06-19       Impact factor: 12.701

9.  Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses' Health Studies.

Authors:  Megan S Rice; Shelley S Tworoger; Kimberly A Bertrand; Susan E Hankinson; Bernard A Rosner; Yvonne B Feeney; Charles V Clevenger; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2014-12-13       Impact factor: 4.624

10.  The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas.

Authors:  Xianquan Zhan; Dominic M Desiderio
Journal:  EPMA J       Date:  2010-06-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.